Published by Hytanbio Tech · Technical guide · 31 October 2026
Two peptides can have the same elemental composition and still differ at one chiral center. During custom synthesis, that difference may arise from epimerization. It deserves its own review because an intact-mass result can look correct while the stereochemistry is wrong.
Where stereochemical changes enter a synthesis
Solid-phase peptide synthesis (SPPS) builds a chain through repeated deprotection and coupling cycles. The sequence, protected amino-acid building blocks, coupling conditions and time spent under base can influence side reactions. The EMA synthetic-peptide guideline lists stereoisomers, deletion and insertion sequences among the variants to consider in medicinal-peptide development. It also asks for attention to the impurity profile of starting materials and intermediates.
Asp-containing sequences need a closer look
Asp-X motifs can form aspartimide under some Fmoc-SPPS conditions. Ring opening may yield α- and β-linked products and change stereochemistry. The risk is sequence-dependent; Asp-Gly is a well-studied example, as described in a peer-reviewed review of aspartimide formation. A process review should name the actual motif and protecting-group strategy instead of treating every Asp-containing peptide as identical.
Build the control plan around the sequence
- Map the sequence: flag susceptible residues, challenging couplings, terminal modifications and any specified D-amino acid.
- Review inputs: verify the identity and stereochemical quality of critical protected amino acids or peptide intermediates.
- Choose process controls: evaluate coupling, capping, deprotection and purification conditions for the identified risks.
- Set analytical evidence: select a method that can resolve the relevant epimer or other close variant; consider an orthogonal technique if peaks co-elute.
- Retain a sample comparison: use the approved sample and its analytical method as a reference when moving to pilot or commercial scale.
The control plan is not a universal recipe. A sequence with an Asp-Gly motif, a peptide assembled from fragments and a short, uncomplicated sequence can need different experiments. The EMA guideline notes that control of diastereomers may require a specific analytical method. A conventional mass spectrum cannot, by itself, resolve an epimer with the same mass.
For a suspected epimer, a development team may prepare or obtain a representative reference, then test whether the chosen chromatographic method separates it from the target under the proposed conditions. Record resolution and detection capability in the method file. If a variant remains co-eluted, report that limitation instead of assigning a reassuring area-percent figure to the target peak. The analytical plan should follow the impurity risk established from the actual route.
Questions to put in a custom-synthesis brief
- Which stereocenters and modifications are intentional in the target sequence?
- Are there motif-specific side reactions expected during the chosen route?
- What analytical method distinguishes the target from its likely stereoisomeric variants?
- Which results will be reported for a development sample, and which for a production lot?
- What process changes trigger a fresh comparison before supply?
Our custom synthesis workflow starts with a feasibility review. Include the sequence, intended use, requested quantity and any known impurity concern in the first enquiry. The protected amino-acid guide provides background on building-block selection.
Frequently asked questions
Will LC-MS reveal an epimer?
Intact mass alone generally will not distinguish molecules that differ only in stereochemistry. A separation method or another suitable orthogonal test must be evaluated for the particular variant.
Does every peptide need the same epimer limit?
No. The relevant controls depend on sequence, route, end use and the applicable specification. Drug-development thresholds should not be copied automatically to cosmetic or research materials.
When should a synthesis route be rechecked?
Review changes to critical building blocks, coupling or deprotection conditions, purification and scale when they may alter the impurity profile.
References and scope
- EMA, Guideline on the Development and Manufacture of Synthetic Peptides (effective 2026).
- Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis.
- Advances in Fmoc Solid-Phase Peptide Synthesis.
Editorial scope: The examples explain route-development risks. They do not describe a tested impurity profile for a specific catalog item. The offered lot’s method and acceptance criteria must be confirmed separately.